Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Seagate Technology Holdings PLC — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Seagate Technology Holdings PLC trades at $785.51 (market cap $183.64B). The key difference: Seagate Technology Holdings PLC is far larger — about 107.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Seagate Technology Holdings PLC for 41 Days on average.
| NUVB | STX | |
|---|---|---|
Market Cap | $1.71B | $183.64B |
Volume | 5,448,712 | 4,409,190 |
Sector | Health | Technology |
52-Week High | $9.54 | $1.09K |
52-Week Low | $3.41 | $211.63 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $1.30B | $185.79B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
STX trades at $774.83, down 3.82% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10, and robust profitability metrics including 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price near support at $773, while analyst consensus remains positive with 53.85% buy ratings and $1,130 price target.
Despite near-term competitive pressures, STX maintains strong earnings momentum and leadership in AI storage markets. The primary risk involves Toshiba's capacity expansion potentially eroding pricing power, but projected 2026 revenue growth to $12.2B and net income of $3.2B support long-term upside. Current valuation at 58.1 P/E reflects growth expectations amid technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
